Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 – MBC
Condition(s):Invasive Breast Cancer; Metastatic Breast Cancer; HR-Positive Breast Cancer; HER2-negative Breast CancerLast Updated:June 28, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Invasive Breast Cancer; Metastatic Breast Cancer; HR-Positive Breast Cancer; HER2-negative Breast CancerLast Updated:June 28, 2022Recruiting
Condition(s):Breast Cancer; Triple Negative Breast Cancer; PD-L1 NegativeLast Updated:March 16, 2022Recruiting
Condition(s):Triple Negative Breast CancerLast Updated:June 9, 2022Recruiting
Condition(s):Urothelial Cancer; Metastatic Urothelial Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Bladder CancerLast Updated:June 1, 2022Recruiting
Condition(s):Breast CancerLast Updated:April 12, 2022Recruiting
Condition(s):Breast Cancer; Triple Negative Breast Cancer; Residual Cancer; Circulating Tumor DNALast Updated:May 27, 2022Recruiting
Condition(s):Advanced Solid Tumors or Triple-negative Breast CancerLast Updated:June 30, 2022Recruiting
Condition(s):Metastatic Solid TumorLast Updated:July 13, 2022Enrolling by invitation
Condition(s):Metastatic Urothelial CarcinomaLast Updated:August 5, 2022Recruiting
Condition(s):Triple Negative Breast Cancer; PD-L1 NegativeLast Updated:May 19, 2022Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.